October 09, 2025

AbbVie US + EU Golden Ticket 2025 – Apply by November 7, 2025

AbbVie US + EU Golden Ticket 2025 – Apply by November 7, 2025
Go back

AbbVie is launching a US and Europe based golden ticket. The award consists of one golden ticket, which provides one year of fully paid individual bench, a desk and membership at one of BioLabs’ operating locations in the US, France or Germany. The award is intended for early-stage biotech companies developing therapeutics (not devices) in the field of migraine.

Additional eligibility requirements are listed below.

More Information

Application requirements 
AbbVie is looking for early-stage biotech companies that fit the following criteria: 

  • Have primary business location in US, France or Germany​
  • Be an early stage-startup focused on developing novel therapeutic approaches for migraine that could include both central and peripheral mechanisms for treating acute migraine and migraine prevention.​
  • Related research areas in pain with potential application(s) to migraine will also be considered.
  • Excluded are devices, neuromodulation technologies and similar technologies.
  • For additional requirements refer to the Terms and Conditions document.

Therapeutic focus of this call for applications: Migraine

Our latest News

discover more
MAGIC: AI-assisted laser tag illuminates cancer origins

MAGIC: AI-assisted laser tag illuminates cancer origins

EMBL researchers have developed a new AI tool, which, through a game of molecular laser tag, identifies cells that can shed light on the earliest origins of cancer Summary The human body relies on precise genetic instructions to function, and cancer begins when these instructions get scrambled. When cells accumulate genetic errors over time, they […]

read more
A human placenta model to protect pregnant women and their babies

A human placenta model to protect pregnant women and their babies

EMBL researchers were awarded a BII foundation grant to support Model-MI – an in vitro model that mimics the maternal-fetal interface Pregnancy is a period of both excitement and concern for the healthy development of the foetus and the well-being of the expectant mother. During the ~40 weeks of gestation, many external factors constitute a danger for […]

read more
Predicting Avian Flu Outbreaks in Europe Using Machine Learning

Predicting Avian Flu Outbreaks in Europe Using Machine Learning

Heidelberg researchers identify local outbreak indicators and develop new regional modeling approach Local factors such as seasonal temperature, the year-dependent water and vegetation index, and data on animal density can be used to predict regional outbreaks of avian flu in Europe. This is the finding of a research team led by epidemiologist, mathematician, and statistician […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp